SCHEMBL805123

SCHEMBL805123

CCc1ccc(-c2cc(Cl)ccc2Cl)o1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.52
S1PR4 O95977 9/20 0.50
HPGD P15428 4/20 0.49
HTT P42858 2/20 0.49
MAPT P10636 4/20 0.46
NPSR1 Q6W5P4 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
USP2 O75604 1/20 0.45
ESR1 P03372 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
SLC9A1 P19634 1/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.44
S1PR2 O95136 4/20 0.44
ALDH1A1 P00352 2/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805163 0.86 ALDH1A1 (0.46) S1PR4HPGDHTTMAPTNPSR1
SCHEMBL27331749 0.83 HPGD (0.53) HSD17B2S1PR4HPGDHTTMAPT
SCHEMBL2056340 0.80 FTO (0.52) HSD17B2HTTMAPTSMN1; SMN2KDM4E
SCHEMBL13749573 0.79 LMNA (0.51) S1PR4HPGDHTTMAPTNPSR1
SCHEMBL10028047 0.77 HPGD (0.53) S1PR4HPGDHTTMAPTNPSR1
SCHEMBL13809597 0.75 S1PR4 (0.52) S1PR4HPGDHTTMAPTNPSR1
SCHEMBL2056342 0.74 ALDH1A1 (0.62) HPGDHTTMAPTNPSR1L3MBTL1
SCHEMBL10000785 0.74 SOS1 (0.69) S1PR4HPGDHTTMAPTNPSR1
SCHEMBL27331752 0.74 KDM4E (0.51) HSD17B2S1PR4MAPTMAPK1KDM4E
SCHEMBL18551806 0.73 CD274 (0.67) HPGDHTTMAPTNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071652-A1 Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof CORNERSTONE THERAPEUTICS, INC. (US) 2012-03-22 US disclosed
US-7943622-B2 Piperazines, pharmaceutical compositions and methods of use thereof CORNERSTONE THERAPEUTICS, INC. (US) 2011-05-17 US disclosed
US-20080051415-A1 Novel piperazines, pharmaceutical compositions and methods of use thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071652-A1 Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof CHRNA7, CHRNA5, CHRNA2 HSD17B2 2653/4885S1PR4 674/4885HPGD 951/4885
US-20080051415-A1 Novel piperazines, pharmaceutical compositions and methods of use thereof CHRNA7, CHRNA5, CHRNA2 HSD17B2 2653/4885S1PR4 674/4885HPGD 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.